Skip to content

Study · Observational study · n = 43 · 2023

16 results

Efficacy and safety profile of Glucagon-Like Peptide-1 Receptor Agonist in obese Type-2 diabetes patients from a private institution in Karachi.

Qasim SF, Ahsan T, Ghaus S, Imran P

Pakistan journal of medical sciences1 Jul 2023

PMID37492314 (opens in a new tab)PMCIDPMC10364304 (opens in a new tab)DOI10.12669/pjms.39.4.7353 (opens in a new tab)PepBankPUB-37492314
Download PDFPubMedAsk about this study
Jump to 16 results

Summary

ObjectiveTo assess the effectiveness of GLP-1RAs in managing obese T2DM patients.MethodsThis prospective cohort analysis was conducted at Medicell Institute of Diabetes, Karachi, Pakistan; from July 2019 to July 2021. A total of 97 obese individuals >16 years of age with T2DM and IGT were initially enrolled, and 81 patients who showed up for the follow-up were prescribed one of the three GLP-1RAs available in Pakistan.ResultsOut of 81 patients who showed up for the follow-up visit, 43 had received Liraglutide, 25 were taking Dulaglutide, and 13 had been prescribed IDegLira supplemented with oral hypoglycemic medications ± insulin. The mean age of the enrolled patients was 49.21(12.44) years, and there was female predominance (55.6%). Overall, there was a significant weight and BMI reduction among the patients treated with either of the GLP-1RAs (P<.01). Furthermore, significant glycemic control was observed in all three groups after the treatment. The Dulaglutide group demonstrated a more significant reduction of HbA1c compared to Liraglutide group, which showed more pronounced weight and BMI reduction. Nevertheless, this class of medications was well-tolerated, with nausea being the most often reported side effect.ConclusionGLP-1RAs showed favorable weight and HbA1c reduction among patients of all three treatment groups.
CC BYText from Europe PMC. Highlighted sentences are the source of results.

Results from this study16

8 results from studies that gave the peptide. 8 results from people.

  1. 01HumanObservational studyEfficacy outcome

    In obese patients with diabetes, liraglutide use was associated with improved glycemic control after treatment.

    In plain wordsIn obese people with diabetes, liraglutide use was linked to improved blood sugar control from baseline.

    Peptide
    Liraglutide
    Outcome
    DecreaseGlycemic control
    Study

    n = 43

    Outcome group
    Glycemic control · Metabolic and weight
    Studied dose
    Dose not stated

    Source sentences

    Summary
    Furthermore, significant glycemic control was observed in all three groups after the treatment.
    2 context sentences
    Summary · context
    This prospective cohort analysis was conducted at Medicell Institute of Diabetes, Karachi, Pakistan; from July 2019 to July 2021.
    Summary · context
    Out of 81 patients who showed up for the follow-up visit, 43 had received Liraglutide, 25 were taking Dulaglutide, and 13 had been prescribed IDegLira supplemented with oral hypoglycemic medications ± insulin.
  2. 02HumanObservational studyEfficacy outcome

    In obese patients with diabetes, dulaglutide use was associated with improved glycemic control after treatment.

    In plain wordsIn obese people with diabetes, dulaglutide use was linked to improved blood sugar control from baseline.

    Peptide
    Dulaglutide (Trulicity)
    Outcome
    DecreaseGlycemic control
    Study

    n = 25

    Outcome group
    Glycemic control · Metabolic and weight
    Studied dose
    Dose not stated

    Source sentences

    Summary
    Furthermore, significant glycemic control was observed in all three groups after the treatment.
    2 context sentences
    Summary · context
    This prospective cohort analysis was conducted at Medicell Institute of Diabetes, Karachi, Pakistan; from July 2019 to July 2021.
    Summary · context
    Out of 81 patients who showed up for the follow-up visit, 43 had received Liraglutide, 25 were taking Dulaglutide, and 13 had been prescribed IDegLira supplemented with oral hypoglycemic medications ± insulin.
  3. 03HumanObservational studyEfficacy outcome

    In obese patients with diabetes, dulaglutide was associated with greater HbA1c reduction than liraglutide.

    In plain wordsIn obese people with diabetes, dulaglutide was linked to greater HbA1c reduction than liraglutide.

    Peptide
    Dulaglutide (Trulicity)
    Outcome
    DecreaseHbA1c comparison
    Study

    n: not reported in source

    Comparator
    Liraglutide
    Outcome group
    Glycemic control · Metabolic and weight
    Studied dose
    Dose not stated

    Source sentences

    Summary
    The Dulaglutide group demonstrated a more significant reduction of HbA1c compared to Liraglutide group, which showed more pronounced weight and BMI reduction.
    2 context sentences
    Summary · context
    This prospective cohort analysis was conducted at Medicell Institute of Diabetes, Karachi, Pakistan; from July 2019 to July 2021.
    Summary · context
    Out of 81 patients who showed up for the follow-up visit, 43 had received Liraglutide, 25 were taking Dulaglutide, and 13 had been prescribed IDegLira supplemented with oral hypoglycemic medications ± insulin.
  4. 04HumanObservational studyEfficacy outcome

    In obese patients with diabetes, liraglutide was associated with less HbA1c reduction than dulaglutide.

    In plain wordsIn obese people with diabetes, liraglutide was linked to less HbA1c reduction than dulaglutide.

    Peptide
    Liraglutide
    Outcome
    IncreaseHbA1c comparison
    Study

    n: not reported in source

    Comparator
    Dulaglutide
    Outcome group
    Glycemic control · Metabolic and weight
    Studied dose
    Dose not stated

    Source sentences

    Summary
    The Dulaglutide group demonstrated a more significant reduction of HbA1c compared to Liraglutide group, which showed more pronounced weight and BMI reduction.
    2 context sentences
    Summary · context
    This prospective cohort analysis was conducted at Medicell Institute of Diabetes, Karachi, Pakistan; from July 2019 to July 2021.
    Summary · context
    Out of 81 patients who showed up for the follow-up visit, 43 had received Liraglutide, 25 were taking Dulaglutide, and 13 had been prescribed IDegLira supplemented with oral hypoglycemic medications ± insulin.
  5. 05HumanObservational studyEfficacy outcome

    In obese patients with diabetes, liraglutide was associated with greater weight reduction than dulaglutide.

    In plain wordsIn obese people with diabetes, liraglutide was linked to greater weight reduction than dulaglutide.

    Peptide
    Liraglutide
    Outcome
    DecreaseWeight comparison
    Study

    n: not reported in source

    Comparator
    Dulaglutide
    Outcome group
    Body weight · Metabolic and weight
    Studied dose
    Dose not stated

    Source sentences

    Summary
    The Dulaglutide group demonstrated a more significant reduction of HbA1c compared to Liraglutide group, which showed more pronounced weight and BMI reduction.
    2 context sentences
    Summary · context
    This prospective cohort analysis was conducted at Medicell Institute of Diabetes, Karachi, Pakistan; from July 2019 to July 2021.
    Summary · context
    Out of 81 patients who showed up for the follow-up visit, 43 had received Liraglutide, 25 were taking Dulaglutide, and 13 had been prescribed IDegLira supplemented with oral hypoglycemic medications ± insulin.
  6. 06HumanObservational studyEfficacy outcome

    In obese patients with diabetes, dulaglutide was associated with less weight reduction than liraglutide.

    In plain wordsIn obese people with diabetes, dulaglutide was linked to less weight reduction than liraglutide.

    Peptide
    Dulaglutide (Trulicity)
    Outcome
    IncreaseWeight comparison
    Study

    n: not reported in source

    Comparator
    Liraglutide
    Outcome group
    Body weight · Metabolic and weight
    Studied dose
    Dose not stated

    Source sentences

    Summary
    The Dulaglutide group demonstrated a more significant reduction of HbA1c compared to Liraglutide group, which showed more pronounced weight and BMI reduction.
    2 context sentences
    Summary · context
    This prospective cohort analysis was conducted at Medicell Institute of Diabetes, Karachi, Pakistan; from July 2019 to July 2021.
    Summary · context
    Out of 81 patients who showed up for the follow-up visit, 43 had received Liraglutide, 25 were taking Dulaglutide, and 13 had been prescribed IDegLira supplemented with oral hypoglycemic medications ± insulin.
  7. 07HumanObservational studyEfficacy outcome

    In obese patients with diabetes, liraglutide was associated with greater BMI reduction than dulaglutide.

    In plain wordsIn obese people with diabetes, liraglutide was linked to greater BMI reduction than dulaglutide.

    Peptide
    Liraglutide
    Outcome
    DecreaseBMI comparison
    Study

    n: not reported in source

    Comparator
    Dulaglutide
    Outcome group
    Body weight · Metabolic and weight
    Studied dose
    Dose not stated

    Source sentences

    Summary
    The Dulaglutide group demonstrated a more significant reduction of HbA1c compared to Liraglutide group, which showed more pronounced weight and BMI reduction.
    2 context sentences
    Summary · context
    This prospective cohort analysis was conducted at Medicell Institute of Diabetes, Karachi, Pakistan; from July 2019 to July 2021.
    Summary · context
    Out of 81 patients who showed up for the follow-up visit, 43 had received Liraglutide, 25 were taking Dulaglutide, and 13 had been prescribed IDegLira supplemented with oral hypoglycemic medications ± insulin.
  8. 08HumanObservational studyEfficacy outcome

    In obese patients with diabetes, dulaglutide was associated with less BMI reduction than liraglutide.

    In plain wordsIn obese people with diabetes, dulaglutide was linked to less BMI reduction than liraglutide.

    Peptide
    Dulaglutide (Trulicity)
    Outcome
    IncreaseBMI comparison
    Study

    n: not reported in source

    Comparator
    Liraglutide
    Outcome group
    Body weight · Metabolic and weight
    Studied dose
    Dose not stated

    Source sentences

    Summary
    The Dulaglutide group demonstrated a more significant reduction of HbA1c compared to Liraglutide group, which showed more pronounced weight and BMI reduction.
    2 context sentences
    Summary · context
    This prospective cohort analysis was conducted at Medicell Institute of Diabetes, Karachi, Pakistan; from July 2019 to July 2021.
    Summary · context
    Out of 81 patients who showed up for the follow-up visit, 43 had received Liraglutide, 25 were taking Dulaglutide, and 13 had been prescribed IDegLira supplemented with oral hypoglycemic medications ± insulin.

Studies that did not test the peptide alone8

In this study, the peptide was a lab tool or a carrier, part of a mix, or the subject of a lab method. These results are not evidence about taking the peptide.

  1. 09HumanNot a test of Dulaglutide (Trulicity) aloneObservational studyEfficacy outcome

    In obese patients with type 2 diabetes, weight was significantly reduced overall among patients treated with pooled GLP-1 receptor agonists (including dulaglutide).

    In plain wordsIn obese people with diabetes, pooled GLP-1 drug treatment, including dulaglutide, was linked to lower weight than at baseline.

    Peptide
    Dulaglutide (Trulicity)
    Outcome
    DecreaseWeight
    Study

    n = 81

    Outcome group
    Body weight · Metabolic and weight

    Source sentences

    Summary
    Overall, there was a significant weight and BMI reduction among the patients treated with either of the GLP-1RAs (P<.01).
    2 context sentences
    Summary · context
    This prospective cohort analysis was conducted at Medicell Institute of Diabetes, Karachi, Pakistan; from July 2019 to July 2021.
    Summary · context
    Out of 81 patients who showed up for the follow-up visit, 43 had received Liraglutide, 25 were taking Dulaglutide, and 13 had been prescribed IDegLira supplemented with oral hypoglycemic medications ± insulin.

    In this study, Dulaglutide (Trulicity) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Dulaglutide (Trulicity).

  2. 10HumanNot a test of Liraglutide aloneObservational studyEfficacy outcome

    In obese patients with type 2 diabetes, weight was significantly reduced overall among patients treated with pooled GLP-1 receptor agonists (including liraglutide).

    In plain wordsIn obese people with diabetes, pooled GLP-1 drug treatment, including liraglutide, was linked to lower weight than at baseline.

    Peptide
    Liraglutide
    Outcome
    DecreaseWeight
    Study

    n = 81

    Outcome group
    Body weight · Metabolic and weight

    Source sentences

    Summary
    Overall, there was a significant weight and BMI reduction among the patients treated with either of the GLP-1RAs (P<.01).
    2 context sentences
    Summary · context
    This prospective cohort analysis was conducted at Medicell Institute of Diabetes, Karachi, Pakistan; from July 2019 to July 2021.
    Summary · context
    Out of 81 patients who showed up for the follow-up visit, 43 had received Liraglutide, 25 were taking Dulaglutide, and 13 had been prescribed IDegLira supplemented with oral hypoglycemic medications ± insulin.

    In this study, Liraglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Liraglutide.

  3. 11HumanNot a test of Dulaglutide (Trulicity) aloneObservational studyEfficacy outcome

    In obese patients with type 2 diabetes, BMI was significantly reduced overall among patients treated with pooled GLP-1 receptor agonists (including dulaglutide).

    In plain wordsIn obese people with diabetes, pooled GLP-1 drug treatment, including dulaglutide, was linked to lower BMI than at baseline.

    Peptide
    Dulaglutide (Trulicity)
    Outcome
    DecreaseBMI
    Study

    n = 81

    Outcome group
    Body weight · Metabolic and weight

    Source sentences

    Summary
    Overall, there was a significant weight and BMI reduction among the patients treated with either of the GLP-1RAs (P<.01).
    2 context sentences
    Summary · context
    This prospective cohort analysis was conducted at Medicell Institute of Diabetes, Karachi, Pakistan; from July 2019 to July 2021.
    Summary · context
    Out of 81 patients who showed up for the follow-up visit, 43 had received Liraglutide, 25 were taking Dulaglutide, and 13 had been prescribed IDegLira supplemented with oral hypoglycemic medications ± insulin.

    In this study, Dulaglutide (Trulicity) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Dulaglutide (Trulicity).

  4. 12HumanNot a test of Liraglutide aloneObservational studyEfficacy outcome

    In obese patients with type 2 diabetes, BMI was significantly reduced overall among patients treated with pooled GLP-1 receptor agonists (including liraglutide).

    In plain wordsIn obese people with diabetes, pooled GLP-1 drug treatment, including liraglutide, was linked to lower BMI than at baseline.

    Peptide
    Liraglutide
    Outcome
    DecreaseBMI
    Study

    n = 81

    Outcome group
    Body weight · Metabolic and weight

    Source sentences

    Summary
    Overall, there was a significant weight and BMI reduction among the patients treated with either of the GLP-1RAs (P<.01).
    2 context sentences
    Summary · context
    This prospective cohort analysis was conducted at Medicell Institute of Diabetes, Karachi, Pakistan; from July 2019 to July 2021.
    Summary · context
    Out of 81 patients who showed up for the follow-up visit, 43 had received Liraglutide, 25 were taking Dulaglutide, and 13 had been prescribed IDegLira supplemented with oral hypoglycemic medications ± insulin.

    In this study, Liraglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Liraglutide.

  5. 13HumanNot a test of Dulaglutide (Trulicity) aloneObservational studySafety outcome

    In obese patients with diabetes, nausea was the most frequently reported side effect across GLP-1 receptor agonist regimens including dulaglutide.

    In plain wordsIn obese people with diabetes, nausea was the most common reported side effect across the pooled regimens, including dulaglutide.

    Peptide
    Dulaglutide (Trulicity)
    Outcome
    Direction not reportedPooled nausea
    Study

    n = 81

    Outcome group
    Gastrointestinal adverse events · Gastrointestinal

    Source sentences

    Summary
    Nevertheless, this class of medications was well-tolerated, with nausea being the most often reported side effect.
    2 context sentences
    Summary · context
    This prospective cohort analysis was conducted at Medicell Institute of Diabetes, Karachi, Pakistan; from July 2019 to July 2021.
    Summary · context
    Out of 81 patients who showed up for the follow-up visit, 43 had received Liraglutide, 25 were taking Dulaglutide, and 13 had been prescribed IDegLira supplemented with oral hypoglycemic medications ± insulin.

    In this study, Dulaglutide (Trulicity) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Dulaglutide (Trulicity).

  6. 14HumanNot a test of Liraglutide aloneObservational studySafety outcome

    In obese patients with diabetes, nausea was the most frequently reported side effect across GLP-1 receptor agonist regimens including liraglutide.

    In plain wordsIn obese people with diabetes, nausea was the most common reported side effect across the pooled regimens, including liraglutide.

    Peptide
    Liraglutide
    Outcome
    Direction not reportedPooled nausea
    Study

    n = 81

    Outcome group
    Gastrointestinal adverse events · Gastrointestinal

    Source sentences

    Summary
    Nevertheless, this class of medications was well-tolerated, with nausea being the most often reported side effect.
    2 context sentences
    Summary · context
    This prospective cohort analysis was conducted at Medicell Institute of Diabetes, Karachi, Pakistan; from July 2019 to July 2021.
    Summary · context
    Out of 81 patients who showed up for the follow-up visit, 43 had received Liraglutide, 25 were taking Dulaglutide, and 13 had been prescribed IDegLira supplemented with oral hypoglycemic medications ± insulin.

    In this study, Liraglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Liraglutide.

  7. 15HumanNot a test of Liraglutide aloneObservational studyEfficacy outcome

    In obese patients with diabetes, IDegLira with oral hypoglycemic medications and optional insulin was associated with improved glycemic control.

    In plain wordsIn obese people with diabetes, the IDegLira combination regimen was linked to improved blood sugar control after treatment.

    Peptide
    Liraglutide
    Outcome
    DecreaseIDegLira glycemic control
    Study

    n = 13

    Outcome group
    Glycemic control · Metabolic and weight

    Source sentences

    Summary
    Furthermore, significant glycemic control was observed in all three groups after the treatment.
    2 context sentences
    Summary · context
    This prospective cohort analysis was conducted at Medicell Institute of Diabetes, Karachi, Pakistan; from July 2019 to July 2021.
    Summary · context
    Out of 81 patients who showed up for the follow-up visit, 43 had received Liraglutide, 25 were taking Dulaglutide, and 13 had been prescribed IDegLira supplemented with oral hypoglycemic medications ± insulin.

    In this study, Liraglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Liraglutide.

  8. 16HumanNot a test of Liraglutide aloneObservational studyEfficacy outcome

    In obese patients with T2DM or IGT, the IDegLira regimen was associated with reduced weight from baseline.

    In plain wordsIn obese patients with diabetes or impaired glucose tolerance, the IDegLira combination regimen was linked to lower weight than at baseline.

    Peptide
    Liraglutide
    Outcome
    DecreaseIDegLira Weight
    Study

    n = 13

    Comparator
    Baseline
    Outcome group
    Body weight · Metabolic and weight

    Source sentences

    Summary
    GLP-1RAs showed favorable weight and HbA1c reduction among patients of all three treatment groups.
    2 context sentences
    Summary · context
    A total of 97 obese individuals >16 years of age with T2DM and IGT were initially enrolled, and 81 patients who showed up for the follow-up were prescribed one of the three GLP-1RAs available in Pakistan.
    Summary · context
    Out of 81 patients who showed up for the follow-up visit, 43 had received Liraglutide, 25 were taking Dulaglutide, and 13 had been prescribed IDegLira supplemented with oral hypoglycemic medications ± insulin.

    In this study, Liraglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Liraglutide.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 3Current

    22 Oct 2026, 02:25 UTC

    Study results updated

  2. Version 2

    21 Oct 2026, 18:59 UTC

    Study data updated · source update from Europe PMC

  3. Version 1

    9 Oct 2026, 03:05 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.